profit from every $100 of sales.
$0$100
Nuwellis
$5.53+5.53% today
-99.6% in 1 year
1-year low $4.581-year high $2,199.75
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nuwellis sold, what it kept, and what it did with the cash.
Sales went from $8.54 million in 2022 to $8.27 million in 2025, with -$17.5 million of profit last year.
SalesProfit
Nuwellis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nuwellis | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Nuwellis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 9 | 9 | 9 | 8 | |
| 5 | 5 | 6 | 5 | |
| -17 | -18 | -11 | -11 | |
| -5 | -16 | -5 | -7 | |
| -15 | -20 | -11 | -18 | |
| -947.80 | -16,934.40 | -353.22 | -25.39 | |
| 55.7% | 56.2% | 64.9% | 62.0% | |
| -201.0% | -198.9% | -125.7% | -134.3% | |
| -170.0% | -228.0% | -127.7% | -211.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 10 | 10 | 6 |
| Cash | 18 | 4 | 5 | 1 |
| Total debt | 1 | 1 | 1 | 0 |
| Total liabilities | 12 | 7 | 3 | 3 |
| 12 | 3 | 7 | 3 | |
| 0 | 0 | 0 | 1 | |
| -31.2% | -332.6% | -62.0% | -186.0% | |
| -117.5% | -629.4% | -171.0% | -666.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -18 | -10 | -11 | |
| 0 | 0 | 0 | 0 | |
| -15 | -18 | -10 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 0 | 0 |
Valuation
- –
- –
- –
- 0.7×
- 0.3×
- –
- –
- -486.4%
- -781.8%
- 0.0%
Profitability
- 62.0%
- -134.3%
- -211.9%
- -90.2%
- -331.8%
- -288.2%
- -6,046.6%
- -286.4%
- -359.9%
- 32.8%
Growth
- −1.1%
- –
- −12.9%
- –
- +670.6%
Financial health
- -0.1×
- 0.13
- 5.4%
- -1.1×
- 1.71
- 1.08
- 1.35
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 888
Bottom 16%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -2.09 | -1.00 | −109.0% |
| Mar 10, 2026 | -1.50 | -1.56 | +3.8% |
| Nov 12, 2025 | 0.56 | -17.22 | +103.3% |
| Aug 14, 2025 | -60.99 | -18.90 | −222.7% |
| May 13, 2025 | -28.99 | -18.91 | −53.3% |
| Mar 11, 2025 | -0.65 | -0.43 | −51.2% |
| Nov 11, 2024 | 1.74 | -1.28 | +235.9% |
| Aug 13, 2024 | -18.85 | -9.49 | −98.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
64Pass
Philip Fisher
43No pass
Peter Lynch
27No pass
Joel Greenblatt
–Not enough data
Charlie Munger
49No pass
Terry Smith
41No pass
Questions about Nuwellis
Is Nuwellis a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nuwellis AI analysis
What does Nuwellis do?
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. It is in Medical - Devices.
Does Nuwellis pay a dividend?
No. Nuwellis does not pay a dividend at the moment.
Is Nuwellis stock halal?
No. Nuwellis does not pass our halal screen: its cash and confirmed interest-bearing investments are 48% of its market value, at or above the 33% limit. How we check
How has Nuwellis stock done over the past year?
Down 99.6% over the past twelve months, to $5.53. It traded between $4.58 and $2,199.75 and is 99.7% below its high.
Who are Nuwellis's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Nuwellis's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.